Scientific Sessions

Pharmacology in cardiology has evolved significantly, with emerging therapies targeting molecular pathways to improve cardiovascular outcomes and patient survival. Traditional drug classes such as beta-blockers, ACE inhibitors, statins, and antiplatelet agents remain central to managing heart failure, hypertension, coronary artery disease, and arrhythmias. However, advances in molecular biology, genomics, and pharmacogenomics have led to the development of novel agents that offer more precise and effective interventions. These include sodium-glucose cotransporter-2 (SGLT2) inhibitors for heart failure, angiotensin receptor-neprilysin inhibitors (ARNIs), selective cardiac myosin activators, and novel lipid-lowering therapies such as PCSK9 inhibitors.

Emerging pharmacological strategies focus on personalized medicine, targeting patient-specific risk factors and disease mechanisms. Anti-inflammatory therapies, RNA-based therapeutics, and gene-targeted drugs aim to modify the underlying pathophysiology of atherosclerosis, myocardial remodeling, and arrhythmias. Combination therapies and advanced drug-delivery systems, including nanoparticles and sustained-release formulations, enhance efficacy while minimizing adverse effects. Clinical trials continue to evaluate these innovative agents for safety, efficacy, and long-term outcomes. By integrating traditional pharmacology with cutting-edge molecular therapies, cardiology is moving toward more individualized, targeted, and effective treatment strategies, improving quality of life and long-term prognosis for patients with cardiovascular disease.